

**CLAIMS**

1. A method for treating inflammatory diseases of the external segment or the anterior segment of the eyes, which  
5 comprises administering an aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof once a day, and maintaining a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the  
10 anterior aqueous humor for at least 24 hours after the intraocular administration.

2. The method according to claim 1, wherein the aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic  
15 acid or its pharmacologically acceptable salt or a hydrate thereof comprises an organic amine or a salt thereof, and the content of the aforementioned organic amine or salt thereof is an amount to allow the octanol-water partition coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid to be 0.7 to 4.

20

3. The method according to claim 1 or claim 2, wherein the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof in the aqueous eye drop is 0.01 to 0.5w/v%.

25

4. The method according to claim 2, wherein the organic amine is at least one member selected from the group consisting of an amino acid, an alkanolamine, a diamine, a piperazine, and an aminoalkylsulfonic acid.

5. The method according to claim 2 or claim 4, wherein the organic amine is an amino acid and its concentration is 0.35 to 5w/v%.

5

6. The method according to claim 2 or claim 4, wherein the organic amine is an alkanolamine and its concentration is 0.15 to 0.95w/v%.

10

7. The method according to claim 6, wherein the alkanolamine is trometamol.

15

8. The method according to claim 2 or claim 4, wherein the organic amine is a diamine and its concentration is 0.05 to 5w/v%.

20

9. The method according to claim 2 or claim 4, wherein the organic amine is a piperazine and it is contained at a concentration of 0.05 to 5w/v% in the aqueous eye drop.

10. The method according to claim 2 or claim 4, wherein the organic amine is an aminoalkylsulfonic acid and its concentration is 0.05 to 5w/v%.

25

11. The method according to claim 10, wherein the aminoalkylsulfonic acid is aminoethylsulfonic acid.

12. A method for promoting intraocular penetration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its

pharmacologically acceptable salt or a hydrate thereof, which comprises administering an aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof  
5 comprises an organic amine or a salt thereof, wherein the content of said organic amine or salt thereof is an amount to allow the octanol-water partition coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid to be 0.7 to 4.

10 13. An aqueous eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, characterized in that a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its  
15 pharmacologically acceptable salt or a hydrate thereof is maintained in the anterior aqueous humor for at least 24 hours by once a day administration.

14. The aqueous eye drop according to claim 13, wherein  
20 the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof in the aqueous eye drop is 0.01 to 0.5w/v%.

15. The aqueous eye drop according to claim 13 or claim  
25 14, wherein the aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof comprises an organic amine or a salt thereof, and the content of said organic amine or salt thereof is an amount to allow the octanol-water partition

coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid contained in the aqueous eye drop to be 0.7 to 4.

16. The aqueous eye drop according to claim 15, wherein  
5 the organic amine is at least one member selected from the group consisting of an amino acid, an alkanolamine, a diamine, a piperazine, and an aminoalkylsulfonic acid.

17. The aqueous eye drop according to claim 15 or claim  
10 16, wherein the organic amine is an amino acid and its concentration is 0.35 to 5w/v%.

18. The aqueous eye drop according to claim 15 or claim  
16, wherein the organic amine is an alkanolamine and its  
15 concentration is 0.15 to 0.95w/v%.

19. The aqueous eye drop according to claim 18, wherein the alkanolamine is trometamol.

20 20. The aqueous eye drop according to claim 15 or claim 16, wherein the organic amine is a diamine and its concentration is 0.05 to 5w/v%.

21. The aqueous eye drop according to claim 15 or claim  
25 16, wherein the organic amine is a piperazine and it is contained at a concentration of 0.05 to 5w/v% in the aqueous eye drop.

22. The aqueous eye drop according to claim 15 or claim 16, wherein the organic amine is an aminoalkylsulfonic acid and

its concentration is 0.05 to 5w/v%.

23. The aqueous eye drop according to claim 22, wherein the aminoalkylsulfonic acid is aminoethylsulfonic acid.

5

24. An aqueous eye drop for once a day for treating inflammatory diseases of the external segment or the anterior segment of the eyes, characterized in that a therapeutically effective concentration of  
10 2-amino-3-(4-bromobenzoyl)phenylacetic acid is maintained in the anterior aqueous humor for at least 24 hours by once a day administration of 0.01 to 0.5w/v% 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and 0.05  
15 to 5w/v% aminoethylsulfonic acid.

25. Use of an organic amine or its salt for producing an aqueous eye drop which is to be administered once a day, characterized in that the aqueous eye drop comprising  
20 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof is administered once a day, and a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is maintained in the anterior aqueous humor for at least 24 hours  
25 by once a day administration to treat inflammatory diseases of the external segment or the anterior segment of the eyes.

26. The use according to claim 25, wherein the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid

or its pharmacologically acceptable salt or a hydrate thereof in the aqueous eye drop is 0.01 to 0.5w/v%.

27. The use according to claim 25 or claim 26, wherein  
5 the amount of the organic amine or its salt used is an amount to allow the octanol-water partition coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid to be 0.7 to 4.

28. The use according to claim 27, wherein the organic  
10 amine is at least one member selected from the group consisting of an amino acid, an alkanolamine, a diamine, a piperazine, and an aminoalkylsulfonic acid.

29. The use according to claim 27 or claim 28, wherein  
15 the organic amine is an amino acid, and its concentration is 0.35 to 5w/v%.

30. The use according to claim 27 or claim 28, wherein  
the organic amine is an alkanolamine, and its concentration is  
20 0.15 to 0.95w/v%.

31. The use according to claim 30, wherein the alkanolamine is trometamol.

25 32. The use according to claim 27 or claim 28, wherein the organic amine is a diamine, and its concentration is 0.05 to 5w/v%.

33. The use according to claim 27 or claim 28, wherein

the organic amine is a piperazine, and it is contained at a concentration of 0.05 to 5w/v% in the aqueous eye drop.

34. The use according to claim 27 or claim 28, wherein  
5 the organic amine is an aminoalkylsulfonic acid, and its concentration is 0.05 to 5w/v%.

35. The use according to claim 34, wherein the aminoalkylsulfonic acid is aminoethylsulfonic acid.